EUVIMEDSkopri EUVIMED
Open access

Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma

Anita Y Voigt iD, Andrew Walter iD, Timothy H Young iD, John P Graham iD, Bruna M Batista Bittencourt iD, Alvaro de Mingo Pulido iD, Karol Prieto iD, Kenneth Y Tsai iD, John P Sundberg iD, Julia Oh iD

Experimental Dermatology · 2023

DOI: 10.1111/exd.14864 ↗

At a glance

Journal article in Experimental Dermatology, 2023. Written by Anita Y Voigt and 9 co-authors. Institution: The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA. Major MEDLINE topics: Carcinoma, Squamous Cell, Immunotherapy, Melanoma, Skin Neoplasms. Cited 13 times so far (Crossref); 43 references. The full text is freely available in PubMed Central. Funded by: NIAMS NIH HHS, NIAID NIH HHS, NCI NIH HHS.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

The gut microbiome is increasingly recognized to alter cancer risk, progression and response to treatments such as immunotherapy, especially in cutaneous melanoma. However, whether the microbiome influences immune checkpoint inhibitor (ICI) immunotherapy response to non‐melanoma skin cancer has not yet been defined. As squamous cell carcinomas (SCC) are in closest proximity to the skin microbiome, we hypothesized that the skin microbiome, which regulates cutaneous immunity, might affect SCC‐associated anti‐PD1 immunotherapy treatment response. We used ultraviolet radiation to induce SCC in SKH1 hairless mice. We then treated the mice with broad‐band antibiotics to deplete the microbiome, followed by colonisation by candidate skin and gut bacteria or persistent antibiotic treatment, all in parallel with ICI treatment. We longitudinally monitored skin and gut microbiome dynamics by 16S rRNA gene sequencing and tumour burden by periodic tumour measurements and histologic assessment. Our study revealed that antibiotics‐induced abrogation of the microbiome reduced the tumour burden, suggesting a functional role of the microbiome in non‐melanoma skin cancer therapy response.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellImmunotherapyMelanomaSkin NeoplasmsGastrointestinal MicrobiomeAnimalsMiceAnti-Bacterial AgentsMicrobiotaRNA, Ribosomal, 16SUltraviolet Rays

Author keywords

SKH1 hairless miceskin microbiomesquamous cell carcinoma

Substances

Anti-Bacterial AgentsRNA, Ribosomal, 16S

Authors and institutions

  • The Jackson Laboratory for Genomic Medicine, Farmington, Connecticut, USA.
  • The Jackson Laboratory, Bar Harbor, Maine, USA.
  • Departments of Anatomic Pathology and Tumor Biology, Moffitt Cancer Center, Florida, USA.

ORCID profiles: Anita Y Voigt, Andrew Walter, Timothy H Young, John P Graham, Bruna M Batista Bittencourt, Alvaro de Mingo Pulido, Karol Prieto, Kenneth Y Tsai, John P Sundberg, Julia Oh

Funding

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • NCI NIH HHS
  • NINDS NIH HHS
  • NIGMS NIH HHS
  • American Cancer Society
  • LEO Pharma Research Foundation
  • National Institutes of Health

Cite

APA

Voigt, A. Y., Walter, A., Young, T. H., Graham, J. P., Batista Bittencourt, B. M., de Mingo Pulido, A., Prieto, K., Tsai, K. Y., Sundberg, J. P., & Oh, J. (2023). Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma. Experimental Dermatology. https://doi.org/10.1111/exd.14864

Vancouver

Voigt AY, Walter A, Young TH, Graham JP, Batista Bittencourt BM, de Mingo Pulido A, et al. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma. Experimental Dermatology. 2023. doi:10.1111/exd.14864

BibTeX
@article{Voigt2023,
  author = {Voigt, Anita Y and Walter, Andrew and Young, Timothy H and Graham, John P and Batista Bittencourt, Bruna M and de Mingo Pulido, Alvaro and Prieto, Karol and Tsai, Kenneth Y and Sundberg, John P and Oh, Julia},
  title = {Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma},
  journal = {Experimental Dermatology},
  year = {2023},
  doi = {10.1111/exd.14864}
}
Start for free →